Skip to main content
An official website of the United States government
Email

Cancer Tissue Engineering Collaborative (TEC)

""

Representative image for the Cancer Tissue Engineering Collaborative

The Cancer Tissue Engineering Collaborative (TEC) Research Program supports the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research. Collaborative, multidisciplinary projects that engage the fields of regenerative medicine, tissue engineering, biomaterials, and bioengineering with cancer biology will be essential for generating novel experimental models that mimic cancer pathophysiology to elucidate specific cancer phenomena that are otherwise difficult to examine in vivo.

The Cancer TEC Research Program catalyzes the advancement of innovative, well characterized in vitro and ex vivo systems available for cancer research, expands the breadth of these systems to several cancer types, and promotes the exploration of cancer phenomena with biomimetic tissue-engineered systems.

History of Cancer TEC

Three workshops have been sponsored by the NCI to assess the status of tissue-engineered systems in cancer and to identify gaps.   In April 2012, a Physical Sciences – Oncology Network (PS-ON) workshop was held to discuss areas where physical sciences principles from tissue engineering and developmental biology could open new avenues in cancer research. Participants highlighted the need for development of synthetic in vitro and ex vivo engineered systems to better probe key factors in tissues and their microenvironment important in cancer. The consensus of the participants was that these factors could be best studied in physiologically relevant and controlled tissue-engineered systems.  

To further explore the status of tissue-engineered technologies in cancer, a second targeted PS-ON workshop on Biomimetic Tissue Engineered Systems for Advancing Cancer Research was held in February 2014. The workshop highlighted examples of how tissue-engineered technologies are currently being applied to cancer research to study angiogenesis, migration, and therapeutic resistance. Workshop participants identified areas for future focus based on existing research and gaps in cancer biology.  

Finally, in April 2015, a joint workshop was held with the National Science Foundation on Additive Manufacturing for Tumor Engineering. The workshop highlighted several barriers to constructing tissue-engineered systems for cancer research, including the need for their robust pathophysiological characterization. Participants recommended the formation of multidisciplinary partnerships to construct and characterize tissue-engineered models of cancer. It was suggested that characterization of systems could include, but not be limited to, biological comparisons of in vivo and clinical datasets.

  • PAR-25-171 - Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional)
  • FAQs from the Cancer TEC funding opportunity announcement

Cancer TEC News

Dr. Michael King et al. developed a multiplex, high-throughput approach using a multichannel pipetting device to study cancer and immune cell mechanotransduction during metastasis.

In describing the new system,  he said, “We hope that this new approach for performing higher throughput mechanobiology research on suspended cells will be useful to the research community.”

Cancer TEC Associate Membership

The goal of the Cancer TEC Associate Membership program is to provide an opportunity for those who are not currently funded by the Cancer TEC program to engage in Cancer TEC activities and potentially form collaborations with Cancer TEC funded investigators. Additional information, including eligibility, expectations of Cancer TEC Associate Members, and the application form, can be found on the Cancer TEC Associate Membership webpage.

Contact for Cancer TEC

For additional information about the TEC, please contact Dr. Steven Becker.

Funded Projects

InstitutionPrincipal Investigator(s)Project Title
Auburn UniversityElizabeth A. Lipke, Michael W. GreeneEngineered Colon Cancer Tissue to Examine the Role of the Obese Microenvironment in Tumor Aggressiveness
Brigham and Women's Hospital Shrike Zhang, Alfredo Quiñones-HinojosaA Bioprinted Volumetric Model of Vascularized Glioblastoma
Columbia UniversityGordana Vunjak-NovakovicCancer Patient on a Chip
Cornell UniversityEsak LeeTissue-Engineered Models of Lymphatic Drainage in Breast Cancer
Ellison InstituteShannon M. MumenthalerA Microengineered Colon Cancer-Chip Designed to Investigate Tumor-Stromal Interactions Driving Cancer Progression
Johns Hopkins UniversityEun Hyun Ahn, Deok-Ho KimEngineered Biomimetic Collective Cancer Invasion Models for Screening Chemotherapeutic Agents
Purdue UniversityLuis Solorio, Michael K. WendtEngineering the Premetastatic Niche
Rice UniversityMichael R. KingEnabling Technology to Study Mechanosensitive and Mechanoresistant Cancer Cells in Flow
University of ArizonaCynthia K. Miranti, Yitshak ZoharBioengineered Prostate-on-Chip: Mechanisms of Stromal Dysregulation in Prostate Cancer
University of Arkansas at FayettevilleYounghye SongInvestigating the Role of Metabolic Rewiring in Breast Tumor Innervation
University of California - IrvineChristopher C. Hughes, Maheswari SenthilA Vascularized Microphysiological System (MPS) Platform for Modeling Peritoneal Carcinomatosis
University of ChicagoMelody A. SwartzProbing Cellular, Molecular and Biomechanical Barriers to Immunotherapy in the Tumor Microenvironment with Organotypic In Vitro Models of the Tumor-Lympho-Immune Interface
University of Illinois at ChicagoJoanna E. Burdette,  Jonathan R. CoppetaDynamic Interactions of the Ovarian-Fallopian Axis in High Grade Serous Ovarian Cancer
University of Illinois at Urbana-ChampaignBrendan A. HarleyPerivascular Tissue Models to Overcome MGMT-Mediated Temozolomide Resistance in Glioblastoma
University of Nevada RenoBahram A. ParvinA Novel Breast Cancer Therapy Based on Secreted Protein Ligands from CD36+ Fibroblasts
University of Texas Southwestern Medical CenterAndrew Z. WangTissue engineered organ-specific cancer metastasis model for cancer research

Associate Members

InstitutionAssociate Member
Children's Hospital Los AngelesMeenakshi Upreti
Cornell UniversityMingming Wu
Drexel UniversityXiao Huang
Duke UniversityWonjae Lee
Emory University/Georgia TechVahid Serpooshan
Harvard University David J. Mooney
Harvard UniversityJennifer Lewis
Illinois Institute of TechnologyAbhinav Bhushan
Lawrence Livermore National LaboratoryClaire Robertson
MD Anderson Cancer CenterXiling Shen
New York Institute of TechnologyKarrer Alghazali
Northeastern UniversityCynthia Hajal
Northwestern UniversityXiao-Nan Li
San Diego State UniversityMauro Tambasco
Sanford Burnham PrebysKevin Tharp
Shahid Beheshti UniversityMehrnaz Mostafavi
St. Jude Children's Research HospitalAnand G. Patel
Stanford UniversityOvijit Chaudhuri
Terasaki InstituteAli Khademhosseini
Texas A&M UniversityShreya A. Raghavan
University of AlabamaShreya S. Rao
University of ArizonaAlexander J. McGhee
University of California, San DiegoShaochen Chen
University of LouisvilleRobert C.G. Martin
University of MarylandXiaoming (Shawn) He
University of MichiganGeeta Mehta
University of Texas at AustinMarissa N. Rylander
University of Texas at DallasJacopo Ferruzzi
University of Texas Southwestern Medical CenterEmina H. Huang
University of Wisconsin-MadisonPamela Kreeger
Washington UniversityEduardo Rosa-Molinar

Past Projects

InstitutionPrincipal Investigator(s)Project Title
Boston UniversityJoe Tien, Celeste M. NelsonEngineered Invasive Human Breast Tumors with Integrated Capillaries and Lymphatics
Brigham and Women’s HospitalShiladitya Sengupta, Ali KhademhosseiniEngineering Personalized Micro-Tumor Ecosystems
Harvard UniversityDavid J. Mooney, Jennifer A. Lewis, F. Stephen Hodi3D Models of Immunotherapy
Massachusetts Institute of TechnologyRoger D. Kamm, David A. Barbie Development of Physiologic Tissue Models to Assess Tumor Explant Response to Immune Checkpoint Blockade
University of California, San FranciscoManish K. Aghi, Sanjay KumarModeling and Druggable-Genome Screening of Glioblastoma Invasion Using Regional Biopsy-Guided Biomaterials Systems
University of Illinois at ChicagoShilpa SantThree-Dimensional Organoid Models to Study Breast Cancer Progression
University of New South WalesKristopher A. Kilian, John A. CoplandMicrotumor Arrays for the Development of Combination Therapies
University of Texas at AustinStephanie K. SeidlitsTissue-Engineered Models of Microvessel-Mediated Glioblastoma Invasion
University of Texas Southwestern Medical CenterEmina H. Huang, Xiling Shen, Michael ShulerAn Organotypic Model Recapitulating Colon Cancer Microenvironment and Metastasis
University of MiamiDaniel Pelaez, J. William Harbour3-Dimensional Retinal Organoid Platform for the Study of Retinoblastoma
University of Wisconsin-MadisonPamela K. Kreeger, Kristyn S. Masters, Paul J. CampagnolaEngineered ECM Platforms to Analyze Progression in High Grade Serous Ovarian Cancer
Yale UniversityRong Fan, Jiangbing ZhouEx Vivo Analysis of Human Brain Tumor Cells in a Microvascular Niche Model
  • Updated:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Cancer Tissue Engineering Collaborative (TEC) was originally published by the National Cancer Institute.”

Email